Brief: Maia Biotechnology Enters 2024 With Robust Clinical Pipeline In Multiple Hard-To-Treat Cancer Indications
17/01/2024 14:04
Jan 17 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY PROVIDES POSITIVE PHASE 2 CLINICAL
UPDATES
FOR LEAD ANTICANCER AGENT AND OUTLINES TARGETED MILESTONES FOR
2024
* MAIA BIOTECHNOLOGY INC - COMPANY ENTERS 2024 WITH ROBUST
CLINICAL PIPELINE IN MULTIPLE HARD-TO-TREAT CANCER INDICATIONS
Source text for Eikon: ID:nBwbBHmQ5a
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale